Fifty years of clinical research by the Leukemia Committee of the Cancer and Leukemia Group B

被引:9
作者
Larson, Richard A.
Stone, Richard M.
Mayer, Robert J.
Schiffer, Charles A.
机构
[1] Univ Chicago, Hematol Oncol Sect, Dept Med, Chicago, IL 60637 USA
[2] Univ Chicago, Ctr Canc Res, Chicago, IL 60637 USA
[3] Dana Farber Canc Inst, Boston, MA 02115 USA
[4] Harvard Univ, Sch Med, Boston, MA 02115 USA
[5] Wayne State Univ, Karmanos Canc Inst, Detroit, MI USA
关键词
D O I
10.1158/1078-0432.CCR-06-9001
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Progress in the care of patients with leukemia has been one of the great success stories in the field of oncology, and clinical research in leukemia has been the "flagship" of the Cancer and Leukemia Group B since the inception of this organization. Lessons learned from the founders emphasis on childhood and adult leukemia have been extended broadly over the past 50 years to virtually all types of malignant diseases, and the Leukemia, Committee has continued to provide leadership and key contributions. The Leukemia Committee is focused on the individualization of treatment based on distinctive biological and clinical characteristics with the aim of increasing efficacy and decreasing nonspecific toxicity. Our clinical trials in leukemia and myeloma have shifted from primarily empirically derived comparisons of different chemotherapeutic regimens to testing novel concepts such as the role of dose intensity, inhibition of specific mechanisms of drug resistance, the use of hematopoietic growth factors and monoclonal antibodies, and the utility of targeted agents. The Cancer and Leukemia Group B was the pioneer among the cooperative groups in the creation of centralized tissue repositories and the incorporation of correlative laboratory studies as an integral feature of clinical trials, a practice now termed "translational research. "Considerable effort: has focused on the identification of important pretreatment characteristics, such as morphologic features, immunophenotype, chromosomal abnormalities, and molecular defects which are significantly associated with outcome in multivariable analyses and which enhance our understanding for the complex biology of these diseases.
引用
收藏
页码:3556S / 3563S
页数:8
相关论文
共 30 条
  • [1] Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720
    Baer, MR
    George, SL
    Dodge, RK
    O'Loughlin, KL
    Minderman, H
    Caligiuri, MA
    Anastasi, J
    Powell, BL
    Kolitz, JE
    Schiffer, CA
    Bloomfield, CD
    Larson, RA
    [J]. BLOOD, 2002, 100 (04) : 1224 - 1232
  • [2] Bloomfield CD, 1998, CANCER RES, V58, P4173
  • [3] Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712)
    Byrd, JC
    Peterson, BL
    Morrison, VA
    Park, K
    Jacobson, R
    Hoke, E
    Vardiman, JW
    Rai, K
    Schiffer, CA
    Larson, RA
    [J]. BLOOD, 2003, 101 (01) : 6 - 14
  • [4] Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011
    Byrd, JC
    Rai, K
    Peterson, BL
    Appelbaum, FR
    Morrison, VA
    Kolitz, JE
    Shepherd, L
    Hines, JD
    Schiffer, CA
    Larson, RA
    [J]. BLOOD, 2005, 105 (01) : 49 - 53
  • [5] STUDIES OF SEQUENTIAL AND COMBINATION ANTIMETABOLITE THERAPY IN ACUTE LEUKEMIA - 6-MERCAPTOPURINE AND METHOTREXATE
    FREI, E
    TRAGGIS, DG
    GENDEL, BR
    HOLLAND, JF
    TAYLOR, R
    EBAUGH, F
    HAURANI, F
    HAYES, DM
    SODEE, DB
    RUNDLES, RW
    WOLMAN, IJ
    JAMES, GW
    GEHAN, E
    SCHROEDER, LR
    FREIREICH, EJ
    ROTHBERG, H
    PINKEL, D
    HOOGSTRATEN, B
    SPURR, CL
    SELWARY, O
    COOPER, T
    [J]. BLOOD, 1961, 18 (04) : 431 - &
  • [6] A COMPARATIVE STUDY OF 2 REGIMENS OF COMBINATION CHEMOTHERAPY IN ACUTE LEUKEMIA
    FREI, E
    HOLLAND, JF
    SCHNEIDERMAN, MA
    PINKEL, D
    SELKIRK, G
    FREIREICH, EJ
    SILVER, RT
    GOLD, GL
    REGELSON, W
    [J]. BLOOD, 1958, 13 (12) : 1126 - 1148
  • [7] FREIREICH EJ, 1963, BLOOD, V21, P699
  • [8] Reducing patient eligibility criteria in cancer clinical trials
    George, SL
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (04) : 1364 - 1370
  • [9] GOTTLIEB AJ, 1984, BLOOD, V64, P267
  • [10] Risk factors for severe neuropsychiatric toxicity in patients receiving interferon alfa-2b and low-dose cytarabine for chronic myelogenous leukemia: Analysis of cancer and leukemia Group B 9013
    Hensley, ML
    Peterson, B
    Silver, RT
    Larson, RA
    Schiffer, CA
    Szatrowski, TP
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (06) : 1301 - 1308